led209 profile

LED209: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3421033
CHEMBL ID	516533
SCHEMBL ID	3396831
MeSH ID	M0524408

Synonym
1-phenyl-3-[4-(phenylsulfamoyl)phenyl]thiourea
CHEMBL516533
SCHEMBL3396831
AKOS003206243
n-phenyl-4-(3-phenylthioureido)benzenesulfonamide
led209
245342-14-7
n-phenyl-4-[[(phenylamino)thioxomethyl]amino]benzenesulfonamide
DTXSID20392338
HY-19748
CS-5400
led-209
J-015557
n-phenyl-4-{[(phenylamino) thioxomethyl]amino}-benzenesulfonamide
BCP15313
led-209;led 209
FT-0717959
EX-A2091
BS-16236
1-phenyl-3-(4-(phenylsulfamoyl)phenyl)thiourea
n-phenyl-4-(((phenylamino)thioxomethyl)amino)benzenesulphonamide
n-phenyl-4-(((phenylamino)thioxomethyl)amino)benzenesulfonamide
benzenesulphonamide, n-phenyl-4-(((phenylamino)thioxomethyl)amino)-
benzenesulfonamide, n-phenyl-4-(((phenylamino)thioxomethyl)amino)-
V62AG9LR2G ,
C74263
n-phenyl-4-[[(phenylamino)thioxomethyl]amino]-benzenesulfonamide
A899542
VJA34214
unii-v62ag9lr2g
AC-35928

Excerpt	Reference	Relevance
"LED209 has desirable pharmacokinetics and does not present toxicity in vitro and in rodents."	( QseC inhibitors as an antivirulence approach for Gram-negative pathogens. Adebesin, AM; Curtis, MM; Falck, JR; Huntley, JF; Lu, B; Moreira, CG; Prasad, RN; Rasko, DA; Russell, R; Sperandio, V; Stewart, D; Taussig, R; Wang, C; Williams, NS; Zhu, C; Zimmern, P, 2014)	1.12

Bioassays (98)

Assay ID	Title	Year	Journal	Article
AID395190	Effect on terbulaline-induced human beta-2-adrenergic receptor activation expressed in HEK293 cells assessed as cAMP release at 5 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395227	Toxicity in CD1 mouse assessed as lymphocyte counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395228	Toxicity in CD1 mouse assessed as monocyte counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395215	Toxicity in CD1 mouse assessed as aspartate transaminase levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395214	Toxicity in CD1 mouse assessed as alanine transferase levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394781	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in cecum at 20 mg/kg administered 24 hrs post-bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394797	Bacteriostatic activity against Francisella tularensis SCHU S4 at 1 uM in presence of epinephrine	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395200	AUC in CD1 mouse at 20 mg/kg, po	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394795	Antibacterial activity against Francisella tularensis SCHU S4 infected C3H HeN mouse assessed as survival at 20 mg/kg, po administered single dose 3 hrs post-bacterial measured after 9 days	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395229	Toxicity in CD1 mouse assessed as eosinophil counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395207	Toxicity in CD1 mouse assessed as change in spleen weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395233	Toxicity in CD1 mouse assessed as hematocrit content at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394791	Inhibition of virulence gene qseC expression in Francisella tularensis SCHU S4 at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394798	Toxicity in C3H HeN mouse at 20 mg/kg, po administered as single dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395238	Toxicity in CD1 mouse assessed as platelet count at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395236	Toxicity in CD1 mouse assessed as mean corpuscular hemoglobin concentration at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395202	AUC in CD1 mouse at 10 mg/kg, iv administered as bolus dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394789	Antibacterial activity against Francisella tularensis SCHU S4 infected in mouse J774 cells assessed as reduction in bacterial CFU at 5 nM relative to control	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394777	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in ileum at 20 mg/kg administered 24 hrs post-bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394771	Bactericidal activity against Escherichia coli 8624 at 1 uM in presence of epinephrine	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395225	Toxicity in CD1 mouse assessed as WBC counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394765	Inhibition of epinephrine-induced EspA protein secretion in Escherichia coli 8624 at 5 nM by Western blot	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394772	Bacteriostatic activity against Escherichia coli 8624 at 1 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394773	Bacteriostatic activity against Escherichia coli 8624 at 1 uM in presence of epinephrine	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394787	Antibacterial activity against Salmonella Typhimurium SL1344 infected in 129x1/SvJ mouse assessed as reduction of bacterial CFU in spleen at 20 mg/kg, po after 48 hrs relative to control	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395216	Toxicity in CD1 mouse assessed as alkaline phosphatase levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394774	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in ileum at 20 mg/kg pretreated before 3 hrs of bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395231	Toxicity in CD1 mouse assessed as RBC counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395241	Antibacterial activity against Escherichia coli assessed as inhibition of shiga toxin expression at 1 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395219	Toxicity in CD1 mouse assessed as phosphate levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394761	Inhibition of AI3-induced Qsec-dependent virulence gene ler expression in Escherichia coli at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395213	Toxicity in CD1 mouse assessed as triglyceride levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394770	Bactericidal activity against Escherichia coli 8624 at 1 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395188	Activation of human beta-1-adrenergic receptor expressed in HEK293 cells assessed as cAMP release at 5 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395199	Terminal half life in CD1 mouse at 20 mg/kg, po	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395237	Toxicity in CD1 mouse assessed as red cell distribution width at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394785	Bacteriostatic activity against Salmonella Typhimurium SL1344 at 1 uM in presence of epinephrine	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394757	Inhibition of [3H]norepinephrine binding to Escherichia coli Qsec at 5 pM by liposome-based scintillation counting assay	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394790	Inhibition of virulence gene mglA expression in Francisella tularensis SCHU S4 at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395204	Toxicity in CD1 mouse assessed as change in heart weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395194	Cmax in CD1 mouse at 20 mg/kg, iv administered as bolus dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394782	Antibacterial activity against Salmonella Typhimurium SL1344 infected in 129x1/SvJ mouse assessed as survival at 20 mg/kg, po administered 3 hrs pre and 3 hrs post-bacterial challenge measured after 24 hrs	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395217	Toxicity in CD1 mouse assessed as total bilirubin levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394759	Inhibition of epinephrine-induced Escherichia coli Qsec autophosphorylation at 5 pM by liposome-based SDS-PAGE	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394766	Inhibition of epinephrine-induced EspA protein secretion in Escherichia coli 8624 at 5 pM by Western blot	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395240	Antibacterial activity against Escherichia coli 8624 assessed as induction of SOS response	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395226	Toxicity in CD1 mouse assessed as neutrophil counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID1583677	Germicidal activity against Lysobacter enzymogenes YC36 at 5 to 10 pM	2020	Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7	Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.
AID394775	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in ileum at 20 mg/kg administered along with bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395234	Toxicity in CD1 mouse assessed as mean corpuscular volume at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394768	Inhibition of epinephrine-induced EspB protein secretion in Escherichia coli 8624 at 5 pM by Western blot	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395210	Toxicity in CD1 mouse assessed as change in brain weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395196	AUC in CD1 mouse at 20 mg/kg, iv administered as bolus dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395209	Toxicity in CD1 mouse assessed as change in thymus weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394767	Inhibition of epinephrine-induced EspB protein secretion in Escherichia coli 8624 at 5 nM by Western blot	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394776	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in ileum at 20 mg/kg administered 3 hrs post-bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394764	Inhibition of AI3-induced Qsec-dependent virulence gene stx2A expression in Escherichia coli at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395224	Toxicity in CD1 mouse assessed as albumin levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395197	Clearance in CD1 mouse at 20 mg/kg, po	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394784	Bacteriostatic activity against Salmonella Typhimurium SL1344 at 1 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395192	Effect on BRL-37344-induced human beta-3-adrenergic receptor activation expressed in HEK293 cells assessed as cAMP release at 5 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394792	Inhibition of virulence gene iglC expression in Francisella tularensis SCHU S4 at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394794	Inhibition of virulence gene mip expression in Francisella tularensis SCHU S4 at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394796	Bacteriostatic activity against Francisella tularensis SCHU S4 at 1 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395198	Cmax in CD1 mouse at 20 mg/kg, po	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394758	Inhibition of [3H]norepinephrine binding to Escherichia coli Qsec at 5 fM by liposome-based scintillation counting assay	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395223	Toxicity in CD1 mouse assessed as creatinine levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394780	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in cecum at 20 mg/kg administered 3 hrs post-bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394762	Inhibition of AI3-induced Qsec-dependent virulence gene eae expression in Escherichia coli at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394783	Antibacterial activity against Salmonella Typhimurium SL1344 infected in 129x1/SvJ mouse assessed as survival at 20 mg/kg, po administered 3 hrs pre and 3 hrs post-bacterial challenge measured after 12 days	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395218	Toxicity in CD1 mouse assessed as glucose levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394760	Inhibition of epinephrine-induced Qsec-dependent virulence gene ler expression in Escherichia coli at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395220	Toxicity in CD1 mouse assessed as serum total protein levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394778	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in cecum at 20 mg/kg pretreated before 3 hrs of bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394788	Inhibition of norepinephrine-induced virulence gene sifA expression in Salmonella Typhimurium at 5 pM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395212	Toxicity in CD1 mouse assessed as cholesterol levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395193	Clearance in CD1 mouse at 20 mg/kg, iv administered as bolus dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395208	Toxicity in CD1 mouse assessed as change in liver weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395211	Toxicity in CD1 mouse assessed as change in body weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395205	Toxicity in CD1 mouse assessed as change in lung weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395222	Toxicity in CD1 mouse assessed as urea nitrogen levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395221	Toxicity in CD1 mouse assessed as calcium levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395195	Terminal half life in CD1 mouse at 20 mg/kg, iv administered as bolus dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394799	Activation of human beta-2-adrenergic receptor expressed in HEK293 cells assessed as cAMP release at 5 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395239	Toxicity in CD1 mouse assessed as mean platelet volume at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395201	Oral bioavailability in CD1 mouse at 20 mg/kg	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395191	Effect on dobutamine-induced human beta-1-adrenergic receptor activation expressed in HEK293 cells assessed as cAMP release at 5 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395206	Toxicity in CD1 mouse assessed as change in kidney weight at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394763	Inhibition of AI3-induced Qsec-dependent virulence gene flhDC expression in Escherichia coli at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394779	Antibacterial activity against Escherichia coli infected in New Zealand white rabbit assessed as inhibition of bacterial colonization in cecum at 20 mg/kg administered along with bacterial challenge	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395230	Toxicity in CD1 mouse assessed as basophil counts at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395189	Activation of human beta-3-adrenergic receptor expressed in HEK293 cells assessed as cAMP release at 5 uM	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394793	Inhibition of virulence gene pdpA expression in Francisella tularensis SCHU S4 at 5 pM by quantitative real-time PCR	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395203	AUC in CD1 mouse at 5 mg/kg, iv administered as bolus dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395235	Toxicity in CD1 mouse assessed as mean corpuscular hemoglobin at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394786	Antibacterial activity against Salmonella Typhimurium SL1344 infected in 129x1/SvJ mouse assessed as reduction of bacterial CFU in liver at 20 mg/kg, po after 48 hrs relative to control	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID394769	Inhibition of Escherichia coli attaching-effacing lesions formation in infected human HeLa cells at 5 pM by FAS test	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
AID395232	Toxicity in CD1 mouse assessed as hemoglobin levels at 20 mg/kg, po administered daily once for 5 days measured 3 days after final dose	2008	Science (New York, N.Y.), Aug-22, Volume: 321, Issue:5892	Targeting QseC signaling and virulence for antibiotic development.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (25.00)	29.6817
2010's	7 (58.33)	24.3611
2020's	2 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (91.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ethoxzolamide Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.	3.25	1	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.45	2	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	2.45	2	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
thiazoles [no description available]	2.04	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	3.25	1	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
menaquinone 6 menaquinone 6: RN given refers to (all-E)-isomer	2.04	1
tachyplesin peptide, tachypleus tridentatus tachyplesin peptide, Tachypleus tridentatus: isolated from the hemocytes of the horseshoe crab (Tachypleus tridentatus); cationic peptide; 17 amino acid residues given in first source	2.25	1
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	7.31	1	glycoside
chitosan [no description available]	2.21	1
pc190723 PC190723: Antibacterial; an inhibitor of FtsZ with potent and selective anti-staphylococcal activity including methicillin- and multi-drug-resistant Staphylococcus aureus; structure in first source	2.04	1

Condition	Relationship Strength	Studies
E coli Infections [description not available]	2.51	2
Francisella tularensis Infection [description not available]	2.04	1
Bacterial Infections, Gram-Negative [description not available]	2.44	2
Salmonella Infections, Animal Infections in animals with bacteria of the genus SALMONELLA.	2.48	2
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	2.51	2
Tularemia A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness.	2.04	1
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	2.44	2
Infection [description not available]	2.11	1
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	2.11	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.15	1
Bacterial Disease [description not available]	2.04	1
Bacterial Infections Infections by bacteria, general or unspecified.	2.04	1

led209

Description

Cross-References

Synonyms (31)

Research Excerpts

Effects

Bioassays (98)

Research

Studies (12)

Market Indicators

Research Demand Index: 17.34

Study Types

led209

Description

Cross-References

Synonyms (31)

Research Excerpts

Effects

Bioassays (98)

Research

Studies (12)

Market Indicators

Research Demand Index: 17.34

Study Types

Related Drugs (10)

Related Conditions (12)